Sponsors (23)
The bill substantially expands and enforces no‑cost access to FDA‑approved HIV prevention services and funds outreach/training—improving prevention for millions—while creating meaningful fiscal, administrative, privacy, and litigation risks that could raise costs and complicate implementation.
Millions of people in public programs will get no‑cost FDA‑approved HIV prevention drugs and associated labs/follow‑up (Medicaid/CHIP enrollees, Medicare Part B/D beneficiaries, FEHB, VA, TRICARE, IHS patients), substantially lowering financial barriers to PrEP/PEP.
Uninsured, underinsured, and underserved communities will gain expanded access through federal grants, navigators, and direct funding to community providers (FQHCs, rural clinics, family planning centers, IHS), increasing PrEP/PEP availability and continuity of care.
The bill reduces administrative barriers—removing preauthorization and banning grandfathered‑plan exemptions—so people can access HIV prevention drugs faster and insured enrollees under older plans gain coverage.
Expanded no‑cost coverage and grant programs will increase federal and plan spending, potentially raising taxpayer costs and insurer drug expenditures that could translate into higher premiums or budget pressures.
Significant administrative and compliance burdens for insurers, state regulators, employers, and providers (new reporting, claims processing changes, state Medicaid/CHIP implementation), increasing operational costs and transition workload.
Collecting and publicly reporting claims data raises privacy and data‑security risks; targeted outreach could also be perceived as stigmatizing by the communities it intends to help.
Based on analysis of 20 sections of legislative text.
Requires no‑cost coverage and mostly bans prior authorization for FDA‑approved HIV prevention drugs and funds education and grants to expand PrEP/PEP access.
Official title: Increase access to pre-exposure prophylaxis to reduce the transmission of HIV.
Introduced March 4, 2026 by Tina Smith · Last progress March 4, 2026
Requires private and federal group health plans to cover FDA‑approved HIV prevention drugs (PrEP/PEP) and related services without cost‑sharing, restricts preauthorization rules, and strengthens confidentiality so family members won’t be notified when someone uses these services. It creates HHS/CDC education campaigns, establishes grant funding to expand access (to states, tribes, clinics, and community groups), directs agencies to monitor and report plan compliance, bars life/disability/long‑term care insurers from discriminating based on use of HIV‑prevention medication, and creates a private right of action for violations. Implements compliance reporting and enforcement steps by HHS in coordination with Labor and Treasury, authorizes funding for education and grant programs through FY2026–FY2030, and makes the Act’s requirements prevail over conflicting laws.